心臓 アミロイドーシス: 診断 と 治療 の 進化: アメリカ 心臓 協会 の 科学 的 な 声明
Circulation
|June 2, 2020
まとめ
トランスチレチンアミロイド心筋病 (ATTR- CM) の早期診断は,効果的な治療に不可欠です. 画像処理の進歩と 新しい治療法は この制限性心筋病の治療法を 変えてきています
科学分野:
- 心臓病科
- 心筋病の研究
- アミロイドーシス研究
背景:
- トランスチレチンアミロイド心筋病 (ATTR- CM) は,制限性心筋病です.
- トランスチレチンの細胞外沉積によって引き起こされる.
- ATTR-CMは,心不全の患者でますます認識されています.
研究 の 目的:
- ATTR-CMの診断と管理のための臨床的実践をガイドする.
- 非侵襲的診断技術の進歩を強調する
- ATTR-CMの現在のおよび将来の治療戦略について議論する.
主な方法:
- ATTR-CMの診断と治療における最近の進歩のレビュー.
- 診断のための非侵襲的なイメージング技術の分析.
- 承認された治療法と進行中の研究の評価
主要な成果:
- 非侵襲的イメージングは,ATTR-CMの正確な診断を可能にし,生検の必要性を軽減します.
- ATTR-CMは心臓機能不全の集団では潜在的に診断不足である.
- 承認された治療法はATTR-CMの新たな治療法を提供します.
結論:
- ATTR- CMの早期発見は,最適な治療結果を得るために不可欠です.
- 非侵襲的な診断手段は 適切な介入の鍵です
- ATTR-CMの管理における満たされていないニーズに対処するために,継続的な研究が必要である.
関連する概念動画
Cardiomyopathy I: Introduction and Classification
828
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
828
Cardiomyopathy III: Hypertrophic Cardiomyopathy
810
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
810
Cardiomyopathy IV: Restrictive Cardiomyopathy
957
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
957
Cardiomyopathy V: Interprofessional Care
761
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
761
Cardiomyopathy VI: Nursing Management
485
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
485
Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747


